Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards the development of novel anti-biofilm therapies

Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards the development of novel anti-biofilm therapies
复制标题

DOI:
10.1016/j.jbiotec.2014.09.003
复制
发表时间:
2014-12-10
影响因子:
4.1
通讯作者:
Hancock, Robert E. W.
Hancock, Robert E. W.
中科院分区:
工程技术3区
文献类型:
--
作者:
Taylor, Patrick K.;Yeung, Amy T. Y.;Hancock, Robert E. W.

文献摘要

被引文献

相似文献

细菌作为称为生物膜的结构化聚集体的生长导致其免受恶劣环境条件如物理和化学应力、剪切力和有限的营养物质可用性的保护。由于这种在不利环境条件下生存的高度适应能力,细菌生物膜对抗生素治疗和免疫清除是不利的。这在医院环境中尤其成问题,在医院环境中,生物膜是慢性和装置相关感染的常见原因,并且对卫生保健系统构成重大负担。针对感染的主要治疗策略是使用抗生素,由于适应性耐药性,抗生素通常不足以清除生物膜感染。因此,需要新的生物膜特异性疗法。生物膜发展的具体特征,如表面粘附,细胞外基质的形成,群体感应,和高度调节的生物膜成熟和分散目前正在研究的目标,以开发新的生物膜特异性治疗。本文以铜绿假单胞菌为例,重点介绍了生物膜的抗生素耐药机制,并讨论了目前研究的新型生物膜特异性治疗方法。(C)2014爱思唯尔有限公司版权所有。
The growth of bacteria as structured aggregates termed biofilms leads to their protection from harsh environmental conditions such as physical and chemical stresses, shearing forces, and limited nutrient availability. Because of this highly adapted ability to survive adverse environmental conditions, bacterial biofilms are recalcitrant to antibiotic therapies and immune clearance. This is particularly problematic in hospital settings where biofilms are a frequent cause of chronic and device-related infections and constitute a significant burden on the health-care system. The major therapeutic strategy against infections is the use of antibiotics, which, due to adaptive resistance, are often insufficient to clear biofilm infections. Thus, novel biofilm-specific therapies are required. Specific features of biofilm development, such as surface adherence, extracellular matrix formation, quorum sensing, and highly regulated biofilm maturation and dispersal are currently being studied as targets to be exploited in the development of novel biofilm-specific treatments. Using Pseudomonas aeruginosa for illustrative purposes, this review highlights the antibiotic resistance mechanisms of biofilms, and discusses current research into novel biofilm-specific therapies. (C) 2014 Elsevier B.V. All rights reserved.